GlaxoSmithKline PLC has disclosed that the Boston U.S. attorney's office is coordinating with the Justice Department in Washington, D.C., to look into the safety and marketing of the antidepressant Paxil. The move expands the agency's Paxil inquiry, already under way in Colorado. GSK declined to comment on the investigation, which was prompted by reports linking the medicine to suicidal behavior.

Related Summaries